Forbion builds immunity
Forbion’s fourth fund bumps up biotech allocation and continues to build newcos
With global investors’ interest in European start-ups rising, Forbion Capital Partners plans to emphasize building new companies from scratch as it invests its fourth fund. The firm hopes that by building strong relationships early in its portfolio companies’ life cycles, Forbion can avoid an increasingly competitive deal-making environment later on as
